1 period filed. Holdings below describe the selected month only.
NPORT-P · filed 2026-05-27
No share classes in the SEC snapshot.
2,774 filed series have no class in company_tickers_mf.json, so no ticker can be reached for them.
N-PORT Item C.4.a
as filed
N-PORT Item C.4.b
21 positions in this filing
| Issuer↕ | In master | CUSIP / ISIN | Asset | Balance↕ | Value↕ | Weight▲ | Country |
|---|---|---|---|---|---|---|---|
| Jiangsu Hengrui Pharmaceutical Jiangsu Hengrui Pharmaceuticals Co Ltd | — | — CNE100006XS6 | EC CORP | 6,200 NS |
| $51.0K HKD |
| 1.229% |
| CN |
| Hanmi Pharm Co Ltd | — | — KR7128940004 | EC CORP | 158 NS | $53.1K KRW | 1.280% | KR |
| Zealand Pharma A/S | — | — DK0060257814 | EC CORP | 1,584 NS | $72.1K DKK | 1.735% | DK |
| Structure Therapeutics Inc | GPCR | 86366E106 US86366E1064 | EC CORP | 1,738 NS | $83.8K | 2.018% | US |
| Viking Therapeutics Inc | VKTX | 92686J106 US92686J1060 | EC CORP | 2,818 NS | $91.7K | 2.209% | US |
| Scholar Rock Holding Corp | SRRK | 80706P103 US80706P1030 | EC CORP | 2,005 NS | $98.6K | 2.374% | US |
| Invesco Government & Agency Po Invesco Government & Agency Portfolio | — | 825252885 US8252528851 | STIV RF | 123,112.5 NS | $123.1K | 2.965% | US |
| Innovent Biologics Inc | — | — KYG4818G1010 | EC CORP | 17,000 NS | $184.1K HKD | 4.434% | CN |
| Roche Holding AG | — | — CH1499059983 | EC CORP | 473 NS | $185.2K CHF | 4.462% | CH |
| Shionogi & Co Ltd | — | — JP3347200002 | EC CORP | 8,500 NS | $185.3K JPY | 4.464% | JP |
| Merck & Co Inc | MRK | 58933Y105 US58933Y1055 | EC CORP | 1,546 NS | $186.0K | 4.479% | US |
| Pfizer Inc | PFE | 717081103 US7170811035 | EC CORP | 6,828 NS | $191.7K | 4.618% | US |
| AstraZeneca PLC | AZN | — GB0009895292 | EC CORP | 980 NS | $193.3K | 4.655% | GB |
| AbbVie Inc | ABBV | 00287Y109 US00287Y1091 | EC CORP | 907 NS | $197.3K | 4.751% | US |
| Arrowhead Pharmaceuticals Inc | ARWR | 04280A100 US04280A1007 | EC CORP | 3,287 NS | $206.1K | 4.964% | US |
| CSPC Pharmaceutical Group Ltd | — | — HK1093012172 | EC CORP | 180,000 NS | $208.9K HKD | 5.032% | CN |
| Chugai Pharmaceutical Co Ltd | — | — JP3519400000 | EC CORP | 4,600 NS | $249.0K JPY | 5.997% | JP |
| Amgen Inc | AMGN | 031162100 US0311621009 | EC CORP | 740 NS | $260.4K | 6.271% | US |
| Regeneron Pharmaceuticals Inc | REGN | 75886F107 US75886F1075 | EC CORP | 364 NS | $281.2K | 6.774% | US |
| Eli Lilly & Co | LLY | 532457108 US5324571083 | EC CORP | 522 NS | $480.1K | 11.564% | US |
| Novo Nordisk A/S | NVO | 670100205 US6701002056 | EC CORP | 13,431 NS | $493.6K | 11.888% | DK |
Positions resolved to the master through ISIN, then rolled up through the taxonomy. 67.8% of reported value reaches a classification.
Percentages are of the reported value of positions above ($4.08M), not of the fund’s net assets ($4.15M). The two differ by cash, derivatives filed with no market value, and rounding.